Biomarker of Exposure Reductions Upon Switching for 5 Days from Cigarettes to a Carbon Heated Tobacco Product (CHTP 1.0)
|
|
- Gerard Ward
- 6 years ago
- Views:
Transcription
1 Biomarker of Exposure Reductions Upon Switching for Days from to a Carbon Heated Tobacco Product () A. Donelli, C. Tran, C. Haziza, J. Ancerewicz, G. de La Bourdonnaye, R. Weitkunat, and F. Lüdicke 8 healthy adult smokers (age of 21+) were randomly assigned to two groups and asked to: (1) switch from cigarettes to (41 participants) or (2) continue to use their own non-menthol cigarettes (39 participants). Participants were eligible if they smoked 1 commercially available non-menthol cigarettes per day for the last 6 weeks prior admission and had smoked cigarettes for 3 consecutive years before enrollment and were not planning to quit smoking in coming 3 months. Intro PMI R&D, Philip Morris Products S.A. Quai Jeanrenaud, 2 Neuchâtel, Switzerland (part of Philip Morris International group of companies) The Carbon Heated Tobacco Product () is designed to heat tobacco without burning it in order to reduce formation of, and consequently exposure to, harmful and potentially harmful constituents (HPHC) as compared to cigarettes while replicating the ritual, taste, sensory characteristics and nicotine uptake of cigarette smoking. The main objective of this study was to demonstrate the reduction of biomarkers of exposure (BoExp) to selected HPHCs in smokers switching from cigarettes to CHTP 1. as compared to smokers continuing to smoke cigarettes for consecutive days. Among other assessments the nicotine uptake and subjective effects of use were evaluated in this study. 1. is a heat-not-burn product that does not involve tobacco combustion 2. The product generates a nicotine-containing aerosol which has significantly lower levels of HPHCs than cigarettes 3. has been designed to resemble a cigarette as closely as possible Selected Harmful or Potentially Harmful Constituents (HPHC) of tobacco smoke 1 HPHCs IN SMOKE Carbon Monoxide Acrolein 1,3-Butadiene Benzene Nicotine Exposure to HPHCs was assessed by measuring the level of corresponding BoExp in urine and plasma. BoExp can be described as substances measured in human body as a result of ingestion of another substance Results REDUCTION IN HPHCs EXPOSURE: VS CIGARETTES (DAY ) NICOTINE UPTAKE Day levels were reduced, relative to cigarettes, by 8.8% to 88.1% in primary biomarkers COHb, MHBMA, 3-HPMA and SPMA. Other biomarkers were reduced by.6% to 97.1%. For more information see the brochure. Neq (mg/g creat) 1 SUBJECTIVE EFFECTS Nicotine (ng/ml) 2 Cotinine (mg/ml) % % Constituent: Acrolein % 1 Constituent: 1,3-Butadiene S-PMA 3 1 Constituent: Carbon Monoxide MHBMA 1 % 3-HPMA Total score 1 COHb Reward (Factor 2) 6 4 CIGARETTES Level of Biomarkers in the group smoking cigarettes Relief (Factor 1) % Constituent: Benzene Total 1-OHP -.6 % Constituent: Pyrene 4-ABP % Constituent: 4-aminobiphenyl 1-NA % 1. NEQ level was 3.% lower for the group compared to the cigarette group over all time points. 2. On day, plasma nicotine and cotinine levels were respectively 3.% lower and 2.6% higher in group than in the cigarette group. 1. Cigarette and users scored the products similarly in the urge-to-smoke assessment questionnaire of relief, reward and total scores. 2. The scoring scales of were close to those of cigarettes over the whole study period. Constituent: 1-aminonaphtalene 2-NA -9.1 % Constituent: 2-aminonaphthalene o-toluidine % Conclusions Constituent: o-toluidine CEMA -8.8 % Constituent: Acrylonitrile HEMA -6.1 % Constituent: Ethylene Oxide 3-HMPMA -7. % At the end of the day exposure period biomarkers of exposure to HPHCs were markedly reduced upon switching to use, whereas nicotine levels were similar to cigarette smoking. Constituent: Crotonaldehyde Total 3-OH-B[a]P % Constituent: Benzo[a]pyrene Total NNAL -7.7 % Smoking urge questionnaire scores indicate similar responses for as for CC, which is encouraging for CHTP adoption as an alternative to CC. NNK Total NNN -7.2 % Constituent: NNN The study was registered at ClinicalTrials.gov (ID: NCT2324) For the competing financial interest see the supplementary brochure Global Forum on Nicotine June 1 17, Warsaw, Poland
2 Biomarker of Exposure Reductions Upon Switching for Days from to a Carbon Heated Tobacco Product () A. Donelli, C. Tran, C. Haziza, J. Ancerewicz, G. de La Bourdonnaye, R. Weitkunat and F. Lüdicke
3 Introduction and Objectives Methods BACKGROUND DESIGN Carbon Heated Tobacco Product (CHTP 1.) is a heat-not-burn tobacco product designed to heat tobacco without burning it in order to reduce formation of, and consequently exposure to, harmful and potentially harmful constituents (HPHC) as compared to cigarettes, and to replicate the ritual, taste, sensory characteristics and nicotine uptake of cigarette smoking. Randomized, controlled, open-label, 2-arm, parallel group -day confinement study in 8 healthy adult smokers who used ad libitum (n = 41) or continued to smoke their own brand of cigarettes (n = 39). The study was conducted in Poland between July 4th and Aug 2th 21, and measured 1 selected HPHCs assessed in 24-hour urine, or blood. MAIN OBJECTIVES To assess the extent of reduced exposure to a number of HPHCs upon complete switch to use compared to continued cigarette smoking. Nicotine uptake, and subjective effects were also evaluated. Screening n = 124 Unmet criteria n = 39 Enrollment n = 8 Safety population n = 8 Discontinued n = Randomization n = 8 n = 41 n = 39 Completion n = 8 2
4 PARTICIPANTS SAMPLE SIZE ESTIMATION 1 Subject judged healthy at screening by the Investigator years of age Caucasians, smoking 1 commercially available non-menthol cigarettes (maximum ISO nicotine yield of 1 mg per cigarette) per day for the last 6 weeks prior to admission, based on self-reporting 3 Smoking cigarettes during the last 3 years prior to enrollment 4 Not planning to quit smoking in coming 3 months, but ready to switch from cigarettes to use for days Participants willing to quit smoking after enrolment were encouraged to do so and referred to a smoking cessation counselor. PRODUCT 1 is a heat-not-burn product that does not involve the combustion of tobacco 2 The product generates a nicotinecontaining aerosol which has significantly lower levels of harmful and potentially harmful constituents (HPHCs) compared to cigarettes 3 has been designed to resemble a cigarette as closely as possible A total of 8 participants randomized at a ratio of 1:1 to or cigarette groups, were considered sufficient to attain >8 % power to show a reduction of % in the concentrations of COHb, 3-HPMA, MHBMA, and S-PMA in the group relative to the cigarette group, using a onesided test with 2. % type I error probability. STATISTICAL METHODS 1 Inferential analysis was performed on the endpoints observed on Day 2 Analysis of covariance on log-transformed Day values to estimate the ratios between the study groups (one sided type I error of 2. %) 3 Adjustment for sex, cigarette use over the 6 weeks before enrollment, and the baseline value of the biomarker KEY POINTS 1 Completely switching to use reduced exposure, compared to cigarettes 2 use led to nicotine uptake comparable to cigarette smoking 3 use led to urge-to-smoke results similar to cigarette smoking 3
5 Results % REDUCTION VS. CIGARETTES (DAY ) Biomarker abbreviation (Biomarker name: smoke constituent) Level of Biomarkers in the group smoking cigarettes 1 % COHb (Carboxyhemoglobin: Carbon Monoxide) -8.8 % 3-HPMA (3-hydroxypropylmercapturic acid: Acrolein) -63. % MHBMA (Monohydroxybutenyl mercapturic acid: 1,3-Butadiene) % S-PMA (S-phenylmercapturic acid: Benzene) % Total 1-OHP (1-hydroxypyrene: Pyrene) -.6 % 4-ABP (4-aminobiphenyl: 4-aminobiphenyl) % 1-NA (1-aminonaphtalene: 1-aminonaphtalene) % 2-NA (2-aminonaphthalene: 2-aminonaphthalene) -9.1 % O-toluidine (O-toluidine: O-toluidine) % CEMA (2-cyanoethylmercapturic acid: Acrylonitrile) -8.8 % HEMA (2-hydroxyethyl mercapturic acid: Ethylene Oxide) -6.1 % 3-HMPMA (3-hydroxy-1-methylpropylmercapturic acid: Crotonaldehyde) -7. % Total 3-OH-B[a]P (3-hydroxybenzo(a)pyrene: Benzo(a)pyrene) % Total NNAL (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: NNK) -7.7 % Total NNN (N-nitrosonornicotine: NNN) -7.2 % 4
6 DEMOGRAPHICS CHTP CC Female n (%) 21 (1.2 %) 2 (1.3 %) Age (Mean ± SD) 34.1 ± ± 11. Daily CC Consumption n (%) 1 19 cig/day 21 (1.2 %) 19 (48.7 %) >19 cig/day 2 (48.8 %) 2 (1.3 %) ISO Nicotine n (%).6 mg 32 (78. %) 34 (87.2 %) >.6 1 mg 9 (22. %) (12.8 %) FTND Total Score Mean (SD).4 (1.78).8 (2.) BIOMARKERS OF EXPOSURE SAFETY 1 Day levels were reduced, relative to cigarettes, by 8.8 % to 88.1 % in primary biomarkers COHb, MHBMA, 3-HPMA and SPMA 2 Other biomarkers were reduced by.6 % to 97.1 % NICOTINE UPTAKE 1 NEQ level was 3. % lower in the CHTP 1. compared to the cigarette group over all time points 2 On day plasma nicotine and cotinine levels were respectively 3. % lower and 2.6 % higher in group as compared to the cigarettes group 1 No serious adverse events were reported during the study 2 31/41 CHTP subjects (7.6%) and 2/39 subjects (1.3%) experienced adverse events (AE) % of AEs were mild and 38.8 % were moderate 4 Occurrence of subjects having cough and headache were higher in the CHTP 1. group (32% vs. % for cough and 46 % vs. 23 % for headache)
7 DAY NICOTINE BIOMARKER LEVELS 1 Neq (mg/g creat) 2 Nicotine (ng/ml) 4 Cotinine (mg/ml) QUESTIONNAIRE ON SMOKING URGE (BRIEF) 6 Relief (Factor 1) Reward (Factor 2) Total score SUBJECTIVE EFFECTS 1 and users scored similarly in the urge-to-smoke assessment questionnaire of relief, reward and total scores 2 The scoring scales of were close to those of cigarettes over the whole study period 6
8 SMOKE CONSTITUENT Biomarker Abbreviation Carbon Monoxide Carboxyhemoglobin COHb Acrolein 3-hydroxypropylmercapturic acid 3-HPMA 1,3-Butadiene monohydroxybutenyl mercapturic acid MHBMA Benzene S-phenylmercapturic acid S-PMA Pyrene 1-hydroxypyrene Total 1-OHP 4-aminobiphenyl 4-aminobiphenyl 4-ABP 1-aminonaphtalene 1-aminonaphtalene 1-NA 2-aminonaphthalene 2-aminonaphthalene 2-NA o-toluidine o-toluidine o-toluidine Acrylonitrile 2-cyanoethylmercapturic acid CEMA Ethylene Oxide 2-hydroxyethyl mercapturic acid HEMA Crotonaldehyde 3-hydroxy-1-methylpropylmercapturic acid 3-HMPMA Benzo(a)pyrene 3-hydroxybenzo(a)pyrene Total 3-OH-B[a]P 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone (NNK) 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol Total NNAL N-nitrosonornicotine (NNN) N-nitrosonornicotine Total NNN Nicotine Nicotine Nicotine Cotinine Cotinine Nicotine equivalents: free nicotine, nicotineglucuronide, free cotinine, cotinine-glucuronide, free trans-3 -hydroxycotinine, trans-3 - hydroxycotinine-glucuronide Neq Conclusions At the end of the day exposure period, biomarkers of exposure to HPHCs were markedly reduced upon switching to CHTP 1. use, whereas nicotine levels were similar to cigarette smoking. Smoking urge questionnaire scores indicate similar responses for as for CC, which is encouraging for CHTP adoption as an alternative to CC. 7
9 MORE INFORMATION The study was registered at ClinicalTrials.gov (ID: NCT2324) COMPETING FINANCIAL INTEREST FOLLOW /PMISCIENCE The research described in this brochure was sponsored by the Philip Morris International group of companies GLOBAL FORUM ON NICOTINE JUNE 1 17, WARSAW, POLAND
A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design.
A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: Study Design. Nathan Gale 1, Mike McEwan 1, Alison Eldridge 1, Neil
More informationScientific Evidence for Evaluating Modified Risk Tobacco Products
Scientific Evidence for Evaluating Modified Risk Tobacco Products Presented to the IOM Committee on Scientific Standards for Modified Risk Tobacco Products May 9 th 2011, Washington DC 1 l Altria Client
More informationHeated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences
Heated Tobacco Technology: Science, Behavior and Avoiding Unintended Consequences Global Forum on Nicotine 2017 Moira Gilchrist PhD Philip Morris International June 16th 2017 Important Information Reduced-Risk
More informationCarl D. D Ruiz 1*, Donald W. Graff 2 and Edward Robinson 3
D Ruiz et al. BMC Public Health (2016) 16:543 DOI 10.1186/s12889-016-3236-1 RESEARCH ARTICLE Open Access Reductions in biomarkers of exposure, impacts on smoking urge and assessment of product use and
More informationRegulatory Toxicology and Pharmacology
Regulatory Toxicology and Pharmacology 64 (2012) S54 S63 Contents lists available at SciVerse ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Reduced
More informationChanges in Biological and Functional Markers after Six Months, in Three Populations: THS 2.2 (IQOS ) Users, Continued Smokers, and Smoking Abstinence
Changes in Biological and Functional Markers after Six Months, in Three Populations: THS 2.2 (IQOS ) Users, Continued Smokers, and Smoking Abstinence Christelle Haziza, PhD Manager Clinical Science Philip
More informationEvaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Aerosol System
Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Aerosol System A. Teichert 1, P. Brossard 1, L. Felber Medlin 1, L. Sandalic 1, J. Ancerewicz 1, M. Franzon
More informationBiomarker Comparisons Between Adult Menthol and Non-Menthol Cigarette Smokers
Biomarker Comparisons Between Adult and Non- Cigarette Smokers Mohamadi A. Sarkar, M.Pharm., Ph.D., Senior Principal Scientist Altria Client Services 1 l Altria Client Services (on behalf of Philip Morris
More informationAir Quality assessment during indoor use of the Tobacco Heating System 2.2
Air Quality assessment during indoor use of the Tobacco Heating System 2.2 THS 2.2. is commercialized under the IQOS brand name Dr Catherine Goujon Ginglinger - Philip Morris International Research & Development,
More informationPrincipal Investigator and Study Center: F. Nobuoka, MD Ageo Medical Clinic, 3133 Haraichi, Ageo City, Saitama , Japan
Page 1 APPENDIX 9: ZRHM-PK-05-JP CLINICAL STUDY SUMMARY The study was conducted in Japan from August to November 2013. Principles as defined in International Conference on Harmonization (ICH) Good Clinical
More informationAnalysis and Evaluation of a Cross-Sectional Study IEA World Congress of Epidemiology 20 th August Saitama, Japan
Analysis and Evaluation of a Cross-Sectional Study IEA World Congress of Epidemiology 20 th August Saitama, Japan A van der Plas, L Prieto, D Skiada, M Dobrynina, G Baker, F Ludicke PMI R&D, Philip Morris
More informationTOBACCO HARM REDUCTION:
TOBACCO HARM REDUCTION: An Overview of PMI s Scientific Approach & Main Results for the Tobacco Heating System (THS) 2.2, a Candidate Modified Risk Tobacco Product Tunis, Tunisia Dr. Nuno Fazenda, on behalf
More informationAir Quality assessment during indoor use of the Tobacco Heating System 2.2
Air Quality assessment during indoor use of the Tobacco Heating System 2.2 THS 2.2. is commercialized under the IQOS brand name Maya Mitova, Catherine Goujon Ginglinger, Michel Rotach, Serge Maeder Philip
More informationCARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING
CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING Athens, Greece Dr. Patrick Picavet, M.D., on behalf of: Baker, Gizelle; Haziza, Christelle; Hoeng, Julia;
More informationCARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING
CARDIOVASCULAR EFFECTS OF THE TOBACCO HEATING SYSTEM (THS) 2.2 COMPARED WITH CONTINUED SMOKING Athens, Greece Dr. Patrick Picavet, M.D., on behalf of: Baker, Gizelle; Haziza, Christelle; Hoeng, Julia;
More informationActual Use Study of the Potential Reduced-Risk Product (RRP): Tobacco Heating System (THS)
Actual Use Study of the Potential Reduced-Risk Product (RRP): Tobacco Heating System (THS) S. Roulet 1, P. Magnani 1, G. Kallischnigg 2, A. Dugan 3, C. Gage 3, C. Kanitscheider 4, M. Apecechea 4, A. Ramazzotti
More informationOncology Drug Development: Phase I Case Studies in Healthy Volunteers. Mike Di Spirito, MSc 22-March-2018 ASCPT
Oncology Drug Development: Phase I Case Studies in Healthy Volunteers Mike Di Spirito, MSc 22-March-2018 ASCPT Overview Tobacco cancer - biomarkers of exposure Interesting science using healthy normal
More informationQuantitative Risk Assessment of Tobacco-Burning and Tobacco-Heating Cigarettes
Quantitative Risk Assessment of Tobacco-Burning and Tobacco-Heating Cigarettes Kristin M. Marano, MS, MPH, CPH Ziad S. Naufal, PhD Michael F. Borgerding, PhD Ryan J. Potts, PhD 66 th TSRC Symposium September
More informationAssessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data
Assessment of the Tobacco Heating System (THS) 2.2, A Candidate Modified Risk Tobacco Product: From Concept to Early Clinical Data Global Forum on Nicotine 2015 Bruce D. Clark PhD Philip Morris International
More informationEvaluation of the Potential for Second-hand Exposure to E-cigarette Aerosol in an Office Environment
Evaluation of the Potential for Second-hand Exposure to E-cigarette Aerosol in an Office Environment Edward A. Robinson, Robert D. Leverette, and Manoj Misra Lorillard Tobacco Company 68 th TSRC Charlottesville,
More informationTobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment
Tobacco Heating System 2.2, A Candidate Modified Risk Tobacco Product: Cardiovascular Disease Risk Assessment Global Forum on Nicotine 2016 Moira Gilchrist PhD Philip Morris International R&D June 17th
More informationHeat-not-Burn Products: Scientific Assessment of Risk Reduction
Heat-not-Burn Products: Scientific Assessment of Risk Reduction Tobacco Merchants Association 2015 Annual Meeting Moira Gilchrist PhD Philip Morris International R&D May 20th 2015 The Objective is Harm
More informationGlobal list of validated analytes available at ABF (in alphabetic order)
Global list of validated analytes available at ABF (in alphabetic order) Analyte (abbreviation) Chemical name 11-dh-TXB 2 11-dehydro-thromboxane B 2 12-HETE 1-MHBMA 1-OH-Nap 1-OH-Phe 1-OH-Pyr Chemical
More informationTobacco Control Research and Education, University of California San Francisco, San Francisco, CA, USA
The Difference between IQOS and Continued Smoking Response to the article entitled PMI s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different
More informationWhat is combustion and why is the absence of combustion important for heat not burn products
What is combustion and why is the absence of combustion important for heat not burn products Global Forum on Nicotine 2017 June 16 th 2017 Thomas Mc Grath PhD PMI R&D, Philip Morris Products S.A., Quai
More informationInvestor Day Reduced-Risk Products Lausanne, September 29, 2016
Investor Day Reduced-Risk Products Lausanne, September 29, 2016 Manuel Peitsch Chief Scientific Officer, Reduced-Risk Products Mirek Zielinski President, Reduced-Risk Products Investor Day Reduced-Risk
More informationReduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessationadd_
RESEARCH REPORT doi:10.1111/j.1360-0443.2009.02780.x Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessationadd_2780 343..355 Dorothy K. Hatsukami 1,2, Michael Kotlyar
More informationAnalysis of 18 Urinary Mercapturic Acids by two Multiplex-LC-MS/MS Methods
Analysis of 18 Urinary Mercapturic Acids by two Multiplex-LC-MS/MS Methods Nikola Pluym, Gerhard Gilch, Gerhard Scherer, Max Scherer ABF, Analytisch-Biologisches Forschungslabor GmbH, München, Germany
More informationEffects of Switching to the Menthol Tobacco Heating System 2.2, Smoking Abstinence, or Continued Cigarette Smoking on Clinically
Nicotine & Tobacco Research, 2018, 173 182 doi:10.1093/ntr/ntx028 Original investigation Received May 27, 2016; Editorial Decision January 18, 2017; Accepted 6 February 2017 Original investigation Effects
More informationUrinary biomarkers of smokers exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach
Biomarkers ISSN: 1354-750X (Print) 1366-5804 (Online) Journal homepage: http://www.tandfonline.com/loi/ibmk20 Urinary biomarkers of smokers exposure to tobacco smoke constituents in tobacco products assessment:
More informationCardiovascular effects of nicotine vs. cigarette smoke
Cardiovascular effects of nicotine vs. cigarette smoke Dr Konstantinos Farsalinos Researcher Onassis Cardiac Surgery Center, Greece University of Patras, Greece National School of Public Health, Athens-Greece
More informationHarmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke;
This document is scheduled to be published in the Federal Register on 04/03/2012 and available online at http://federalregister.gov/a/2012-07727, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationExposure and Kinetics of Polycyclic Aromatic Hydrocarbons (PAHs) in Cigarette Smokers
pubs.acs.org/crt Exposure and Kinetics of Polycyclic Aromatic Hydrocarbons (PAHs) in Cigarette Smokers Gideon St.Helen, Maciej L. Goniewicz, Delia Dempsey, Margaret Wilson, Peyton Jacob, III, and Neal
More informationThe importance of offering adult smokers a portfolio of potentially less harmful products
The importance of offering adult smokers a portfolio of potentially less harmful products International Symposium on Nicotine Technology June 15 th 2017 Thomas Mc Grath, PhD PMI R&D, Philip Morris Products
More informationExperimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes
Global Forum on Nicotine Rethinking Nicotine 2018 Experimental trial on the effectiveness of IQOS compared to e-cigarettes and regular tobacco cigarettes Effects on acute craving, withdrawal, positive
More informationThe fitness for purpose of existing tobacco product test methods identifying the gaps
The fitness for purpose of existing tobacco product test methods identifying the gaps Wright C., Ticha J. and Mariner D. British American Tobacco, Research & Development, Southampton UK IG4, 1 th October
More informationBiomarker (BMK) Sub-Group 2017 Report
Biomarker (BMK) Sub-Group 2017 Report Kitzbühel, Austria October 10, 2017 Coordinator: G. L. Prasad Secretary: Kirk Newland Scientific Commission Liaison: Paul Harp Biomarker Sub-Group Objectives Objective
More informationEmbargo Copy - Not for Distribution
Page 1 of 1 Embargo Copy - Not for Distribution Adolescent Exposure to Toxic Volatile Organic Chemicals From E-Cigarettes Mark L. Rubinstein, MD, Kevin Delucchi, PhD, Neal L. Benowitz, MD, Danielle E.
More informationA FRAMEWORK FOR THE ASSESSMENT OF REDUCED RISK TOBACCO AND NICOTINE PRODUCTS
A FRAMEWORK FOR THE ASSESSMENT OF REDUCED RISK TOBACCO AND NICOTINE PRODUCTS Frazer Lowe, Ian M. Fearon, Oscar M. Camacho, Emmanuel Minet and James Murphy British American Tobacco (Investments) Limited
More informationPROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL
PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. ' 423, Approved and Ordered APR 2 2001.01111mork Lieutenant Governor Executive Council Chambers, Victoria On
More informationComparisons Between Adult Menthol and Non-Menthol Smokers Total Exposure Study. Mohamadi Sarkar, M.Pharm., Ph.D Altria Client Services
Comparisons Between Adult and Non- Smokers Total Exposure Study ohamadi Sarkar,.Pharm., Ph.D Altria Client Services 1 Altria Client Services (on behalf of Philip orris USA) Presentation to the Tobacco
More informationThe IQOS Heating System
The IQOS Heating System Tobacco Products Scientific Advisory Committee January 24, 2018 CC-1 Introduction Moira Gilchrist, PhD Vice President Scientific and Public Communications Philip Morris International
More informationAssessing Consumer Responses to RRP: Experience at PMI in Developing Fit-for-Purpose Self-Report Instruments
Assessing Consumer Responses to RRP: Experience at PMI in Developing Fit-for-Purpose Self-Report Instruments C. Chrea, E. Spies, E. Afolalu, N. Mainy, S. Gallot, P. Binggeli, E. Clerc, R. Weitkunat PMI
More informationReduced-Risk Products Science Update
Reduced-Risk Products Science Update Dr. Ian Jones, PhD JTI VP, Reduced-Risk Products Science Forward-Looking Statements This presentation contains forward-looking statements. These statements appear in
More informationExploring five common claims about e-cigarette use. Lion Shahab, PhD University College
Exploring five common claims about e-cigarette use Lion Shahab, PhD University College London @LionShahab Claim 1: Renormalisation Claim 1: Renormalisation A priori predictions for impact on population
More informationUK E-Cigarette Summit Relative risks of cancer posed by combustible and vapourising forms of nicotine delivery: Evidence from chemical exposures
UK E-Cigarette Summit 2017 Relative risks of cancer posed by combustible and vapourising forms of nicotine delivery: Evidence from chemical exposures Ed Stephens University of St Andrews Scope of presentation
More informationΕΝΑΛΛΑΚΤΙΚΕΣ ΜΟΡΦΕΣ ΚΑΠΝΙΣΜΑΤΟΣ
ΕΝΑΛΛΑΚΤΙΚΕΣ ΜΟΡΦΕΣ ΚΑΠΝΙΣΜΑΤΟΣ E CIGARETTE ENDS:ELECTRONIC NICOTINE DELIVERY S Y S TEM) ΗΕΑΤ-ΝΟΤ-ΒURN CIGARETTES (IQOS) Κουρέα Καλλιρρόη Καρδιολόγος NICOTINE DELIVERY SYSTEMS NICOTINE DELIVERY SYSTEMS
More informationProduct Standards for Reducing Nicotine in Cigarettes
Funding Research reported in this publication was supported by the National Institute on Drug Abuse and Food and Drug Administration Center for Tobacco Products (U54 DA031659). The content is solely the
More informationHow innovation will deliver a smokefree
How innovation will deliver a smokefree future Innovation and Good Practices in the Health Sector Rui Minhos Head of Regional Scientific Engagement Philip Morris International 6th November 2018 Our contact
More informationE-cigarettes and personal vapourisers: current research and policy
E-cigarettes and personal vapourisers: current research and policy Declaration of interest I have no links with any e-cigarette manufacturers I have received no funding from the tobacco or pharmaceutical
More informationGlobal impact of FDA-inspired tobacco regulatory science on jobs for chemists
Global impact of FDA-inspired tobacco regulatory science on jobs for chemists Sarah Cooney and Chris Proctor Group Research & Development, British American Tobacco, UK American Chemical Society Fall Meeting,
More informationMight Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re
Might Smoking Rates go up in Flames? Dr John Schoonbee, Chief Medical Officer, Swiss Re 2 Agenda Smoking is still a problem Stopping is hard Electronic cigarettes Reduced Risk tobacco products Males >15yr
More informationBecause PMI application did not report the full range of HPHCs in IQOS aerosol,
Because PMI application did not report the full range of HPHCs in IQOS aerosol, characterize HPHCs in sidestream emissions, include a non-targeted analysis of chemicals in emissions, or conduct clinical
More informationTHE INFLUENCE OF CIGARETTE FILTER DESIGN ON THE YIELD AND COMPOSITION OF CIGARETTE SMOKE
THE INFLUENCE OF CIGARETTE FILTER DESIGN ON THE YIELD AND COMPOSITION OF CIGARETTE SMOKE Dr M J Taylor Director of Scientific Development Essentra Scientific Services CORESTA Congress Quebec 12 to 16 October
More informationLow-Nitrosamine Dissolvable Tobacco Products Star Scientific, Inc. Part III Initiation and Cessation
Low-Nitrosamine Dissolvable Tobacco Products Star Scientific, Inc. Part III Initiation and Cessation Using science to reduce tobacco-related harm at every level of the population 1 Summary - Parts I &
More informationSmoking Behavior and Exposure to Tobacco Toxicants during 6 Months of Smoking Progressively Reduced Nicotine Content Cigarettes
Research Article Cancer Epidemiology, Biomarkers & Prevention Smoking Behavior and Exposure to Tobacco Toxicants during 6 Months of Smoking Progressively Reduced Nicotine Content Cigarettes Neal L. Benowitz,
More informationThe IQOS Heating System
The IQOS Heating System Tobacco Products Scientific Advisory Committee January 24, 2018 CC-1 Introduction Moira Gilchrist, PhD Vice President Scientific and Public Communications Philip Morris International
More informationHarmful and potentially harmful constituents in e-cigarettes
Harmful and potentially harmful constituents in e-cigarettes Prof. Riccardo Polosa Institute of Internal Medicine Centre for the Prevention and Cure of Tabagism University of Catania - ITALY Global Forum
More informationElectronic Cigarettes, Nicotine and Policy Implications
Electronic Cigarettes, Nicotine and Policy Implications Neal L Benowitz MD University of California San Francisco The E-Cigarette Summit The Royal Society London November 17, 2016 Disclosures Dr Benowitz
More informationNon Clinical Toxicology of Nicotine and Aerosol from a Heated Tobacco Product. Patrick Vanscheeuwijck, PhD Director Pre-Clinical Toxicology
Non Clinical Toxicology of Nicotine and Aerosol from a Heated Tobacco Product Patrick Vanscheeuwijck, PhD Director Pre-Clinical Toxicology PMI s Goal for Harm Reduction Offering adult smokers satisfying
More informationThe IQOS Heating System
Script and Slides of Philip Morris International s Presentation before the Tobacco Products Scientific Advisory Committee (TPSAC) 24 January 2018 Slide 1 The IQOS Heating System Tobacco Products Scientific
More informationNew & Emerging Tobacco Products. Linda Bauld & Kamran Siddiqi
New & Emerging Tobacco Products Linda Bauld & Kamran Siddiqi Outline Electronic cigarettes Heat not burn tobacco Smokeless tobacco Waterpipes Terminology E-cigarettes are not a single product Debate about
More informationMenthol Addition to Cigarettes Using Breakable Capsules in the Filter. Impact on the Mainstream Smoke Yields of the Health Canada List Constituents
pubs.acs.org/crt Terms of Use Menthol Addition to Cigarettes Using Breakable Capsules in the Filter. Impact on the Mainstream Smoke Yields of the Health Canada List Constituents C. Dolka,* J.-J. Piade,
More informationTobacco Blend Style. Dinah Winter, Martin Coleman, Nigel Warren
Tobacco Blend Style Dinah Winter, Martin Coleman, Nigel Warren Tobacco Blends 100% lamina tobaccos: Virginia Burley (uncased) 50:50 Virginia/Burley Mix Oriental Examined: Blend component differences Relationships
More informationSmoking and Non-Communicable Diseases in Hong Kong
Smoking and Non-Communicable Diseases in Hong Kong Current Status and the Way Forward Prof. David Khayat Former Head of Medical Oncology at the Pitié-Salpêtrière in Paris Former President of the National
More informationMenthol Cigarette Report
Menthol Cigarette Report Tobacco Products Scientific Advisory Committee Meeting July 15, 2010 Corinne G. Husten, MD, MPH Senior Medical Advisor Center for Tobacco Products, FDA 1 Menthol Cigarette Report
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK ISO/IEC 17025: 2005 Essentra Scientific Services Contact: Mr A Stutz Shaftesbury Avenue Tel: +44 (0)191 428 0100 Jarrow Fax: +44 (0)191 428
More informationSmoking, e-cigs and reduced risk products. Dr John Schoonbee, IMS November 2017
Smoking, e-cigs and reduced risk products Dr John Schoonbee, IMS November 2017 2 The storyline smoking is bad yet many folks still smoke because quitting is very hard is it better, if one cannot quit,
More informationThe Family Smoking Prevention and Tobacco
Call to Establish Constituent Standards for Smokeless Tobacco Products Irina Stepanov, PhD Dorothy Hatsukami, PhD Objectives: To summarize evidence supporting the establishment of constituent standards
More informationE-Cigarettes: Current Perspective
E-Cigarettes: Current Perspective Aruni Bhatnagar, Ph.D. Professor of Medicine University of Louisville Louisville, KY Electronic Cigarettes E-cigarettes are electronic nicotine delivery systems (ENDS),
More informationResearch and Development Department, R.J. Reynolds Tobacco Company, Winston-Salem, N.C , USA Dixon Consultancy, Liphook Hampshire, UK
Beiträge zur Tabakforschung International Contributions to Tobacco Research Volume 26 @ No. 6 @ June 2015 DOI: 10.1515/cttr-2015-0013 Changes in Biomarkers of Exposure and Subjective Effects When Smokers
More informationSupplementary Online Content
Supplementary Online Content Goniewicz ML, Smith DM, Edwards KC, et al. Comparison of nicotine and toxicant exposure in users of electronic cigarettes and combustible cigarettes. JAMA etw Open. 2018;1(8):e185937.
More informationClinical Effects. Jane Y. Lewis, Ph.D. Senior Vice President, Health & Analytical Sciences Altria Client Services
Clinical Effects Jane Y. Lewis, Ph.D. Senior Vice President, Health & Analytical Sciences Altria Client Services 1 l Altria Client Services (on behalf of Philip Morris USA) l Presentation to the Tobacco
More informationEnvironmental and occupational toxicants
unit 3. assessing exposure to the environment chapter 9. Environmental and occupational toxicants Frank de Vocht, Jelle Vlaanderen, Andrew C. Povey, Silvia Balbo, and Roel Vermeulen Summary Biological
More informationLung Cancer Epidemiology & Prevention. A/Prof Fraser Brims
Lung Cancer Epidemiology & Prevention A/Prof Fraser Brims Introduction Lung cancer burden Global, Australia, WA Current smoking rates Other risks and associations Prevention Tobacco control E-cigarettes
More informationPhilip Morris International R&D, Philip Morris Products S.A., Switzerland. 2
Comparative assessment of lung inflammation, pulmonary function and emphysema caused by the aerosol from potential Reduced Risk Products and cigarette smoke in mouse models of COPD. 11 July, 216 COPD-216
More informationUsing the Balanced-Placebo Design for Parsing Nicotine Administration Effects
Using the Balanced-Placebo Design for Parsing Nicotine Administration Effects Thomas H. Brandon, Ph.D. & Amanda M. Palmer, M.A. Moffitt Cancer Center University of South Florida Tampa, Florida, USA Global
More informationCancer and its Causes in Korea
Cancer and its Causes in Korea Prof. Dr. David Khayat, MD, PhD Former Head of Medical Oncology at Pitié-Salpêtrière in Paris Former President of the National Cancer Institute in France Harm Reduction Consultant
More informationStudy Summary Study THS-PBA-02-US
Page 1 Study Summary Study THS-PBA-02-US Study Title: Sponsor: Qualitative Study to Develop THS 2.2 Hypothetical Product Messages Philip Morris International Management S.A. Avenue de Rhodanie, 50 1007
More informationThe Chemical Constituents in Cigarettes and Cigarette Smoke: Priorities for Harm Reduction
The Chemical Constituents in Cigarettes and Cigarette Smoke: Priorities for Harm Reduction A Report to the New Zealand Ministry of Health March 2000 Jefferson Fowles, Ph.D. Toxicologist, Environmental
More informationDavid S. Goya, DO, MBA, FCCP, FACP Kaiser Permanente Medical center Santa Clara, California
* * David S. Goya, DO, MBA, FCCP, FACP Kaiser Permanente Medical center Santa Clara, California None Electric Cigarette was patented in 1965 by Herbert Gilbert First introduced into the marketplace in
More informationNicotine Reduction Workshop Role of nicotine in smoking behaviour
Nicotine Reduction Workshop Role of nicotine in smoking behaviour Derek Mariner APSTW02 11 October 2016 2016 CORESTA Congress, Berlin, Germany, 9-13 October 2016 Introduction Nicotine itself is not especially
More informationFacts & Issues. Tobacco in Australia. A comprehensive online resource. tobaccoinaustralia.org.au
Tobacco in Australia A comprehensive online resource Facts & Issues tobaccoinaustralia.org.au Book excerpt List of chapters available at tobaccoinaustralia.org.au Introduction Chapter 1 Chapter 2 Chapter
More informationThe Effects of Cigarette Smoking
The Effects of Cigarette Smoking by Tschen Min Wang Copyright May 2016, Your Name and Koni Stone The leading preventable cause of death in the United States of America is cigarette smoking. According to
More informationTobacco-related risk perceptions in the regulation of tobacco products at the FDA Center for Tobacco Products
Tobacco-related risk perceptions in the regulation of tobacco products at the FDA Center for Tobacco Products David B. Portnoy, PhD, MPH Conrad J. Choiniere, PhD Office of Science FDA, Center for Tobacco
More informationVariation in Smoke Toxicant Yields from Selected Cigarettes
Variation in Smoke Toxicant Yields from Selected Cigarettes lison Eldridge (SSPT), Tatiana Betson (P), Kevin Mcdam 2013 COREST Joint Study Group Meetings SSPT Seville, Spain / 29 Sept - 3 Oct P Brufa di
More informationI n 1996, the RJ Reynolds Tobacco Company (RJR) began test
ii64 NICOTINE DISCLOSURE Eclipse: does it live up to its health claims? J Slade, G N Connolly, D Lymperis... See end of article for authors affiliations... Correspondence to: Gregory N Connolly, Massachusetts
More informationpp mono2-section 1.qxd 30/04/ :24 Page 1189 INVOLUNTARY SMOKING
INVOLUNTARY SMOKING 1. Composition, Exposure and Regulations 1.1 Composition 1.1.1 Secondhand smoke During smoking of cigarettes, cigars, pipes and other tobacco products, in addition to the mainstream
More informationHOPE OR HAZARD? What Research Tells Us About Potentially Reduced-Exposure Tobacco Products
HOPE OR HAZARD? What Research Tells Us About Potentially Reduced-Exposure Tobacco Products Hope or Hazard? What Research Tells Us About Potentially Reduced-Exposure Tobacco Products. TABLE TABLE OF OF
More informationA DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY. Yan Zhong
Phenanthrene Tetraols as Probes for the Metabolic Activation of Carcinogenic Polycyclic Aromatic Hydrocarbons in Humans A DISSERTATION SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY
More informationIt is important to split the health issues into their two distinct components-
E Cigarettes One major point to make at the outset:- It is important to split the health issues into their two distinct components- -The health of the wider public in the context of new take up of e-cigariettes
More informationResponsible Practice in E-Vapour Products (EVP) Product Stewardship
Responsible Practice in E-Vapour Products (EVP) Product Stewardship Tanvir Walele, MSc, ERT 11 October 2016 1 Responsible Practice Responsible practice can be divided in to 3 areas: Pre-market product
More informationWork in progress in relation to Articles 9 and 10 of the WHO FCTC
Conference of the Parties to the WHO Framework Convention on Tobacco Control Sixth session Moscow, Russian Federation,13 18 October 2014 Provisional agenda item 4.6 FCTC/COP/6/14 24 July 2014 Work in progress
More informationModelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery
Global Nicotine Forum 2018 Modelling the effects of user exposure to harmful emissions across the spectrum of nicotine delivery Ed Stephens University of St Andrews Declaration: No conflicts of interest
More informationSupplementary Online Content
Supplementary Online Content Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical
More informationFDA S CENTER FOR TOBACCO PRODUCTS: AN UPDATE ON REGULATORY ACTIVITIES AND PRIORITIES
FDA S CENTER FOR TOBACCO PRODUCTS: AN UPDATE ON REGULATORY ACTIVITIES AND PRIORITIES Mitch Zeller, J.D. (Director, FDA CTP) Matthew R. Holman, Ph.D. (Director, Office of Science, FDA CTP) Kathy Crosby
More informationreducing smokers exposure to cigarette smoke toxicants
reduced toxicant prototypes reducing smokers exposure to cigarette smoke toxicants inside: scientific challenges tobacco toxicants building a prototype testing Group Research & Development Southampton
More informationUniversity of Toronto Governing Council
University of Toronto Governing Council Smoking Policy April 4, 1995 To request an official copy of this policy, contact: The Office of the Governing Council Room 106, Simcoe Hall 27 King s College Circle
More informationIntroduction. Principles
NHS Health Scotland s position statement on Electronic Nicotine Delivery Systems ENDS - e-cigarettes and other smoking simulator products 31 October 2014 Introduction NHS Health Scotland is the national
More informationElectronic cigarettes for smoking cessation
Electronic cigarettes for smoking cessation Results from the most recent Cochrane update Jamie Hartmann-Boyce*, Hayden McRobbie, Chris Bullen, Rachna Begh, Lindsay F Stead, Peter Hajek *Cochrane Tobacco
More information